$0.1490
0.00110.74%
最終更新: Oct 2, 4:23 AM
$0.1444
-0.0035-2.37%
Benzinga
Benzinga
Benzinga
金曜日, 10 02
Benzinga
© 2026 Benzinga | All Rights Reserved
Vivos Therapeutics (VVOS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.40 | $-0.45 | $-0.47 | $-0.52 |
| Actual | $-0.31 | $-0.52 | $-0.58 | $-0.49 |
| Surprise | +22.5% | -15.6% | -23.4% | +5.77% |
| Revenue | ||||
| Estimate | $5.7M | $5.0M | $7.3M | $4.7M |
| Actual | $5.2M | $5.1M | $3.8M | $6.8M |
| Surprise | -10.0% | +2.02% | -47.3% | +45.0% |
| Metric | Q3 '26E | Q4 '26E | Q2 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-0.30 | $-0.24 | $-0.55 |
| Revenue | |||
| Consensus | $5.5M | $6.0M | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 14, 2026 | $-0.31 | $-0.40 | 22.5 % |
| Q1 | May 20, 2026 | $-0.52 | $-0.45 | -15.6 % |
| Q4 | Apr 15, 2026 | $-0.58 | $-0.47 | -23.4 % |
| Q3 | Nov 19, 2025 | $-0.49 | $-0.52 | 5.77 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 14, 2026 | $5.15M | $5.73M | -10.0 % |
| Q1 | May 20, 2026 | $5.14M | $5.04M | 2.02 % |
| Q4 | Apr 15, 2026 | $3.82M | $7.26M | -47.3 % |
| Q3 | Nov 19, 2025 | $6.78M | $4.68M | 45.0 % |